CDKN2A and head and neck cancer: An unintended byproduct of the rise in HPV-positive OPSCCs has been the shedding of light on the elected surrogate marker p16INK4a [8], which is well known to oncologists and clinicians dealing with cervical cancers and less known to otolaryngologists and researchers in the field of head and neck cancers.